NCT02876978 - Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

April 30, 2019

Conditions

Lung Squamous Cell Carcinoma

Interventions

GENETIC

CAR-GPC3 T Cells

Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.

DRUG

Fludarabine

30 mg/m\^2/day x 4 days

DRUG

Cyclophosphamide

500 mg/m\^2/day x 2 days

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital,Shanghai Jiaotong University, Shanghai